ダウンストリームプロセシングの市場規模：最終ユーザー別、事業規模別、生体分子タイプ別、地域別、2024年～2031年

ダウンストリームプロセシング市場の評価、2024年～2031年

ダウンストリームプロセシング市場は、バイオ医薬品需要の増加、慢性疾患の有病率の上昇、シングルユース技術の採用拡大などの要因によって、今後数年間で大きく成長する見込みです。Verified Market Researchのアナリストによると、ダウンストリーム加工市場は、2024年の299億3,000万米ドルを上回る1,001億8,000万米ドルに達すると予測されています。

企業は効率性と拡張性を向上させるために継続的に技術革新を行っており、市場のダイナミックさと競争力を確保しています。これにより、2024年から2031年にかけて、市場はCAGR 16.30%で成長します。

ダウンストリームプロセシング市場定義/概要

ダウンストリームプロセシングとは、生物学的製品が生産された後に行われる重要な工程を指します。これは、最初に見つかった複雑な混合物から目的の生成物を分離・精製することです。この混合物はしばしば発酵ブロスと呼ばれ、細胞、不要なタンパク質、栄養素、その他の細胞製品別を含むことがあります。

ダウンストリームプロセシングは、生物学的供給源から価値ある製品を得る上で重要な役割を果たします。インスリンやワクチンのようなバイオ医薬品の精製、食品製造のような工業プロセスに必要な酵素の単離、植物や微生物から薬効のある天然物の抽出などに使用されます。要するに、細胞や生物から生の出力を取り出し、私たちが健康や様々な産業用途のために頼りにしている純粋で機能的な製品に変換するのです。

ダウンストリームプロセシング市場の需要を急増させる要因とは？

生物またはその細胞プロセスに由来する医薬品のカテゴリーであるバイオ医薬品に対する需要の高まりは、ダウンストリームプロセシングの主要な促進要因です。バイオ医薬品には、標的特異性の高さ、副作用の少なさ、複雑な疾患の治療能力など、従来の医薬品にはない利点がいくつかあります。このため、インスリン、がん治療用モノクローナル抗体、遺伝子治療薬などのバイオ医薬品の開発と生産が急増しています。その結果、これらの複雑な分子を精製・分離するための、効率的でスケーラブルなダウンストリームプロセシング技術に対する需要が著しく高まっています。

さらに、がん、糖尿病、自己免疫疾患などの慢性疾患の増加は、世界中のヘルスケアシステムに大きな負担を強いています。これらの慢性疾患は長期にわたる治療を必要とすることが多く、バイオ医薬品はこの闘いにおける貴重な武器であることが証明されつつあります。例えば、バイオ医薬品は血糖値を調整することで糖尿病の管理に役立ったり、従来の化学療法薬よりも正確にがん細胞を狙い撃ちすることで、患者の副作用を最小限に抑えたりすることができます。世界人口の高齢化が進み、慢性疾患の発生率が上昇し続ける中、効果的なバイオ医薬品治療に対する需要はそれに比例して増加し、ダウンストリームプロセシング市場を前進させると思われます。

ダウンストリームプロセシング市場の成長を阻害する要因は？

ダウンストリームプロセシングは非常に高価な試みになり得る。特にクロマトグラフィーシステムや限外濾過装置には多額の設備費がかかります。また、クロマトグラフィー用樹脂やフィルターなどの消耗品もコスト増につながります。さらに、ダウンストリームプロセシング装置の操作やメンテナンス、プロセス効率の確保には、熟練した労働力が不可欠です。専門性が要求されるため、有資格者の確保は困難であり、その給与は生産コストに大きく影響します。

さらに、ダウンストリームプロセシングは本質的に複雑であり、精製される特定の製品に合わせた多数の工程が含まれます。高収率を達成し、厳しい純度要件を満たすためには、各工程を注意深く最適化する必要があります。この最適化プロセスには時間がかかり、クロマトグラフィー、ろ過、タンパク質生化学などの分野の専門知識が必要となります。ダウンストリームプロセシングの複雑さは、中小企業や初めてバイオ医薬品製造に参入する企業にとって大きな課題となり得る。効率的な精製プロセスを開発・導入するための専門知識やリソースが社内になく、市場で効果的に競争する妨げとなる可能性があります。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 ダウンストリームプロセシング市場：最終ユーザー別

• バイオ医薬品企業
• 医薬品製造受託機関（CMO）
• 学術研究所・研究機関

第5章 ダウンストリームプロセシング市場：事業規模別

• 大規模ダウンストリームプロセシング
• 中規模ダウンストリームプロセシング
• 小規模ダウンストリームプロセシング

第6章 ダウンストリームプロセシング市場：生体分子タイプ別

• タンパク質・抗体
• ワクチン
• 酵素

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Lonza Group
• Thermo Fisher Scientific Inc.
• Danaher Corporation（Pall Corporation）
• Sartorius Stedim Biotech S.A.
• Merck KGaA（Merck Millipore）
• 3M Company
• Eppendorf AG
• GE Healthcare
• Bio-Rad Laboratories, Inc.
• Boehringer Ingelheim

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Downstream Processing Market Valuation - 2024-2031

The downstream processing market is expected to grow significantly in the coming years, driven by factors such as the increasing demand for biopharmaceuticals, the rising prevalence of chronic diseases, and the growing adoption of single-use technologies. According to the analyst from Verified Market Research, the downstream processing market is estimated to reach a valuation of 100.18 USD Billion over the forecast subjugating around 29.93 USD Billion valued in 2024.

Companies are continually innovating to improve efficiency and scalability, ensuring the market's dynamic and competitiveness. It enables the market to grow at aCAGR of 16.30% from 2024 to 2031.

Downstream Processing Market: Definition/ Overview

Downstream processing refers to the crucial steps taken after a biological product has been produced, typically through fermentation or cell culture. It's all about isolating and purifying the desired product from the complex mixture it's initially found in. This mixture, often called fermentation broth, can contain cells, unwanted proteins, nutrients, and other cellular byproducts.

Downstream processing plays a critical role in obtaining valuable products from biological sources. It's used to purify biopharmaceuticals like insulin and vaccines, isolate enzymes needed for industrial processes like food production, and extract natural products with medicinal properties from plants and microorganisms. In essence, it takes the raw output from cells or organisms and transforms it into the pure and functional products we rely on for health and various industrial applications.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Factors that Surge the Demand for the Downstream Processing Market?

The rising demand for biopharmaceuticals, a category of drugs that are derived from living organisms or their cellular processes, is a major driver for downstream processing. Biopharmaceuticals offer several advantages over traditional medications, including higher target specificity, fewer side effects, and the ability to treat complex diseases. This has led to a surge in the development and production of biopharmaceuticals, such as insulin, monoclonal antibodies for cancer treatment, and gene therapies. As a result, the demand for efficient and scalable downstream processing techniques to purify and isolate these complex molecules has grown significantly.

Furthermore, the increasing prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders places a significant burden on healthcare systems worldwide. These chronic conditions often require long-term treatment, and biopharmaceuticals are proving to be a valuable weapon in this fight. For instance, biopharmaceuticals can help manage diabetes by regulating blood sugar levels or target cancer cells more precisely than traditional chemotherapy drugs, minimizing side effects for patients. As the global population ages and the incidence of chronic diseases continues to rise, the demand for effective biopharmaceutical treatments will correspondingly increase, propelling the downstream processing market forward.

What Factors Hinder the Growth of the Downstream Processing Market?

Downstream processing can be a very expensive endeavor. The cost of equipment can be significant, especially for chromatography systems and ultrafiltration units. Consumables, such as chromatography resins and filters, also add to the bottom line. Furthermore, skilled labor is essential for operating and maintaining downstream processing equipment and ensuring process efficiency. The specialization required can make it challenging to find qualified personnel, and their salaries can contribute significantly to production costs.

Furthermore, Downstream processing is inherently complex, involving a multitude of steps tailored to the specific product being purified. Each step needs to be carefully optimized to achieve high yields and meet stringent purity requirements. This optimization process can be time-consuming and requires specialized expertise in areas like chromatography, filtration, and protein biochemistry. The complexity of downstream processing can pose significant challenges for smaller companies or those venturing into biopharmaceutical production for the first time. They may lack the in-house expertise or resources to develop and implement efficient purification processes, hindering their ability to compete effectively in the market.

Category-Wise Acumens

How Does the Increasing Demand for Biopharmaceutical Companies Contribute the Market Growth?

According to VMR analysis, the biopharmaceutical companies segment is estimated to hold the largest market share during the forecast period. Biopharmaceutical companies are the primary producers of drugs, vaccines, and other biopharmaceuticals. They require robust downstream processing capabilities to handle large-scale production volumes and ensure consistent product quality. Academic labs and research institutes typically work with smaller quantities for research purposes and may not require such extensive downstream processing infrastructure.

Furthermore, Biopharmaceutical companies are constantly striving to improve downstream processing efficiency and scalability. This is crucial for keeping production costs down and meeting growing market demands. Contract Manufacturing Organizations (CMOs), while offering downstream processing services, cater to a wider range of clients with varying needs. Biopharmaceutical companies often have the resources to invest in advanced, scalable downstream processing technologies, giving them an edge.

How does large-scale downstream processing Propel the Growth of the Downstream Processing Market?

The large-scale downstream processing segment is estimated to dominate the Downstream Processing market during the forecast period driven by the surge in demand for biopharmaceuticals, particularly for established drugs and therapies, which necessitates large-scale production to meet market needs. Large-scale downstream processing allows biopharmaceutical companies to achieve higher production volumes efficiently.

Furthermore, Large-scale operations benefit from economies of scale in several ways. Bulk purchasing of raw materials and consumables for downstream processing can lead to lower costs per unit. Additionally, large-scale facilities can potentially streamline processes and optimize resource utilization, further enhancing efficiency. For example, a large-scale facility might implement automated equipment and continuous processing techniques, which can reduce labor costs and improve throughput compared to smaller-scale batch processing. large facilities can leverage their buying power to negotiate better deals with suppliers of chromatography resins, filters, and other essential materials.

Country/Region-wise Acumens

How does Heightened Awareness of the Downstream Processing market Influence Growth in North America?

According to VMR analysts, North America is estimated to dominate the Downstream Processing market during the forecast period. North America boasts a well-established and strong pharmaceutical and biopharmaceutical industry. This translates to a high demand for downstream processing capabilities to support the production of various biopharmaceuticals.

North America has a well-developed healthcare infrastructure with stringent regulatory frameworks for biopharmaceutical production. This focus on quality necessitates advanced downstream processing methods to ensure product safety and efficacy.

Furthermore, Governments in North America, recognizing the potential of biopharmaceuticals to improve public health and drive economic growth, often provide significant funding and support for research and development in biopharmaceutical technologies. This financial backing fuels innovation in downstream processing techniques, encouraging the development of more efficient, scalable, and cost-effective methods for purifying biopharmaceuticals. Additionally, government grants and tax incentives can stimulate private sector investment in R&D, further accelerating advancements in downstream processing technologies. This strong focus on research fosters a collaborative environment where universities, research institutions, and biopharmaceutical companies can work together to develop next-generation downstream processing solutions.

What Factors Contribute to the Potential Opportunities in the Asia Pacific Region?

The Asia Pacific region is estimated to exhibit the highest growth within the Downstream Processing Market during the forecast period. The Asia-Pacific region is home to a vast and growing patient population. This, coupled with a rising middle class with more disposable income for healthcare, creates a significant market for biopharmaceuticals. This translates to a need for expanded downstream processing facilities to meet the anticipated demand. Additionally, As economies in the region flourish, governments are investing heavily in healthcare infrastructure and biopharmaceutical research. This surge in activity creates a strong demand for downstream processing capabilities to support large-scale biopharmaceutical production.

Furthermore, There's a growing emphasis on research and development (R&D) in the Asia-Pacific biopharmaceutical sector. This focus on innovation fosters collaboration between universities, research institutions, and biopharmaceutical companies. This collaborative environment can accelerate advancements in downstream processing technologies, leading to the development of more efficient, scalable, and cost-effective purification methods. Additionally, Regulatory frameworks for biopharmaceutical production in the Asia-Pacific region are becoming more streamlined and harmonized. This can ease the process for companies looking to establish downstream processing facilities in the region.

Competitive Landscape

The downstream processing market is a competitive landscape characterized by a dynamic interplay between established industry leaders and emerging companies with innovative technologies. Well-entrenched players leverage their vast experience, extensive product portfolios, and global reach to maintain a strong market presence.

Some of the prominent players operating in the Downstream Processing Market include:

Lonza Group

Thermo Fisher Scientific Inc.

Danaher Corporation (Pall Corporation)

Sartorius Stedim Biotech S.A.

Merck KGaA (Merck Millipore)

3M Company

Eppendorf AG

GE Healthcare

Bio-Rad Laboratories, Inc.

Boehringer Ingelheim

Latest Developments

In December 2024, Lonza Group partnered with a leading biotechnology company to develop and manufacture a novel gene therapy for a rare genetic disorder. Lonza's expertise in downstream processing will be crucial in purifying and isolating the large quantities of viral vectors needed for this gene therapy treatment. This collaboration highlights the growing importance of downstream processing in bringing innovative biopharmaceutical therapies to patients

In 2024, Thermo Fisher Scientific launched a new chromatography resin specifically designed for high-throughput protein purification. This innovative resin boasts a unique ligand chemistry that offers superior binding capacity and faster purification times for a wide range of protein targets. This can significantly improve the efficiency of downstream processing workflows, especially for biopharmaceutical companies working on large-scale production of protein-based drugs or therapeutics. The new resin is also designed to be compatible with high-flow chromatography systems, further accelerating protein purification processes.

In 2024, Danaher Corporation (Pall Corporation) introduced a new generation of single-use filters for improved performance and scalability in downstream processing.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Downstream Processing Market, By Final User

• Biopharmaceutical Companies
• Contract Manufacturing Organisations (CMOs)
• Academic labs and research institutes

5. Downstream Processing Market, By Operational Scale

• Large-Scale Downstream Processing
• Medium-Scale Downstream Processing
• Small-Scale Downstream Processing

6. Downstream Processing Market, By Biomolecule Type

• Proteins and Antibodies
• Vaccines
• Enzymes

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Lonza Group
• Thermo Fisher Scientific Inc.
• Danaher Corporation (Pall Corporation)
• Sartorius Stedim Biotech S.A.
• Merck KGaA (Merck Millipore)
• 3M Company
• Eppendorf AG
• GE Healthcare
• Bio-Rad Laboratories, Inc.
• Boehringer Ingelheim

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References